Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy Laboratories has reported a consolidated net sales of $542m for the first quarter ended March 31, 2010, an increase of 65%, compared to $313m for the comparable period in 2009.
Subscribe to our email newsletter
For the first quarter of 2010, Ranbaxy Laboratories has posted a EBITDA of $298m, compared to a loss of $201m for the prior year period.
Profit after tax (PAT) was $210m, compared to loss of $153m for the year ago period. Operational PAT, excluding forex translations, was $143m, compared to loss of $5m for the prior year period.
Atul Sobti, CEO and managing director of Ranbaxy, said: “Solid growth in key geographies, along with optimal delivery value from First-to-File opportunities in the US, ensured that we achieved yet another quarter of strong operational performance. We also launched Project Viraat, a comprehensive program aimed at India leadership, in January, 2010.”